tetano
Editor, Senior Moderator
Mol Cell Proteomics
. 2023 May 19;100579.
doi: 10.1016/j.mcpro.2023.100579. Online ahead of print. A new cellular interactome of SARS-CoV-2 nucleocapsid protein and its biological implications
Yuan-Qin Min[SUP] 1 [/SUP], Mengzhuo Huang[SUP] 2 [/SUP], Kuan Feng[SUP] 3 [/SUP], Yajie Jia[SUP] 4 [/SUP], Xiulian Sun[SUP] 5 [/SUP], Yun-Jia Ning[SUP] 6 [/SUP]
Affiliations
There is still much to uncover regarding the molecular details of SARS-CoV-2 infection. As the most abundant protein, coronavirus nucleocapsid (N) protein encapsidates viral RNAs, serving as the structural component of ribonucleoprotein and virion, and participates in transcription, replication, and host regulations. Virus-host interaction might give clues to better understand how the virus affects or is affected by its host during infection and identify promising therapeutic candidates. Considering the critical roles of N, we here established a new cellular interactome of SARS-CoV-2 N by using a high-specific affinity purification (S-pulldown) assay coupled with quantitative mass spectrometry and immunoblotting validations, uncovering many N-interacting host proteins unreported previously. Bioinformatics analysis revealed that these host factors are mainly involved in translation regulations, viral transcription, RNA processes, stress responses, protein folding and modification, and inflammatory/immune signaling pathways, in line with the supposed actions of N in viral infection. Existing pharmacological cellular targets and the directing drugs were then mined, generating a drug-host protein network. Accordingly, we experimentally identified several small molecule compounds as novel inhibitors against SARS-CoV-2 replication. Furthermore, a newly identified host factor, DDX1, was verified to interact and colocalize with N mainly by binding to the NTD domain of the viral protein. Importantly, loss/gain/reconstitution-of-function experiments showed that DDX1 acts as a potent anti-SARS-CoV-2 host factor, inhibiting the viral replication and protein expression. The N-targeting and anti-SARS-CoV-2 abilities of DDX1 are consistently independent of its ATPase/helicase activity. Further mechanism studies revealed that DDX1 impedes multiple activities of N including the N-N interaction, N oligomerization, and N-viral RNA binding, thus likely inhibiting viral propagation. These data provide new clues to better depiction of the N-cell interactions and SARS-CoV-2 infection and may help inform the development of new therapeutic candidates.
Keywords: DDX1; SARS-COV-2; antiviral drug; host restriction factor; interactome; mass spectrometry; nucleocapsid (N) protein; virus-host interaction.
. 2023 May 19;100579.
doi: 10.1016/j.mcpro.2023.100579. Online ahead of print. A new cellular interactome of SARS-CoV-2 nucleocapsid protein and its biological implications
Yuan-Qin Min[SUP] 1 [/SUP], Mengzhuo Huang[SUP] 2 [/SUP], Kuan Feng[SUP] 3 [/SUP], Yajie Jia[SUP] 4 [/SUP], Xiulian Sun[SUP] 5 [/SUP], Yun-Jia Ning[SUP] 6 [/SUP]
Affiliations
- PMID: 37211047
- DOI: 10.1016/j.mcpro.2023.100579
There is still much to uncover regarding the molecular details of SARS-CoV-2 infection. As the most abundant protein, coronavirus nucleocapsid (N) protein encapsidates viral RNAs, serving as the structural component of ribonucleoprotein and virion, and participates in transcription, replication, and host regulations. Virus-host interaction might give clues to better understand how the virus affects or is affected by its host during infection and identify promising therapeutic candidates. Considering the critical roles of N, we here established a new cellular interactome of SARS-CoV-2 N by using a high-specific affinity purification (S-pulldown) assay coupled with quantitative mass spectrometry and immunoblotting validations, uncovering many N-interacting host proteins unreported previously. Bioinformatics analysis revealed that these host factors are mainly involved in translation regulations, viral transcription, RNA processes, stress responses, protein folding and modification, and inflammatory/immune signaling pathways, in line with the supposed actions of N in viral infection. Existing pharmacological cellular targets and the directing drugs were then mined, generating a drug-host protein network. Accordingly, we experimentally identified several small molecule compounds as novel inhibitors against SARS-CoV-2 replication. Furthermore, a newly identified host factor, DDX1, was verified to interact and colocalize with N mainly by binding to the NTD domain of the viral protein. Importantly, loss/gain/reconstitution-of-function experiments showed that DDX1 acts as a potent anti-SARS-CoV-2 host factor, inhibiting the viral replication and protein expression. The N-targeting and anti-SARS-CoV-2 abilities of DDX1 are consistently independent of its ATPase/helicase activity. Further mechanism studies revealed that DDX1 impedes multiple activities of N including the N-N interaction, N oligomerization, and N-viral RNA binding, thus likely inhibiting viral propagation. These data provide new clues to better depiction of the N-cell interactions and SARS-CoV-2 infection and may help inform the development of new therapeutic candidates.
Keywords: DDX1; SARS-COV-2; antiviral drug; host restriction factor; interactome; mass spectrometry; nucleocapsid (N) protein; virus-host interaction.